

Yeast Models of Phosphomannomutase 2 Deficiency, a Congenital Disorder of Glycosylation

Jessica P. Lao,¹ Nina DiPrimio, Madeleine Prangle, Feba S. Sam, Joshua D. Mast, and Ethan O. Perlstein

Perlara PBC, 6000 Shoreline Court, South San Francisco, California

ORCID IDs: 0000-0001-8003-8460 (J.P.L.); 0000-0002-2246-0580 (J.D.M.); 0000-0002-4734-4391 (E.O.P.)

ABSTRACT Phosphomannomutase 2 Deficiency (PMM2-CDG) is the most common monogenic congenital disorder of glycosylation (CDG) affecting at least 800 patients globally. PMM2 orthologs are present in model organisms, including the budding yeast *Saccharomyces cerevisiae* gene *SEC53*. Here we describe conserved genotype-phenotype relationships across yeast and human patients between five PMM2 loss-of-function missense mutations and their orthologous *SEC53* mutations. These alleles range in severity from folding defective (hypomorph) to dimerization defective (severe hypomorph) to catalytic dead (null). We included the first and second most common missense mutations – R141H, F119L respectively – and the most common compound heterozygote genotype – PMM2^{R141H/F119L} – observed in PMM2-CDG patients. Each mutation described is expressed in haploid as well as homozygous and heterozygous diploid yeast cells at varying protein expression levels as either *SEC53* protein variants or PMM2 protein variants. We developed a 384-well-plate, growth-based assay for use in a screen of the 2,560-compound Microsource Spectrum library of approved drugs, experimental drugs, tool compounds and natural products. We identified three compounds that suppress growth defects of *SEC53* variants, F126L and V238M, based on the biochemical defect of the allele, protein abundance or ploidy. The rare PMM2 E139K protein variant is fully functional in yeast cells, suggesting that its pathogenicity in humans is due to the underlying DNA mutation that results in skipping of exon 5 and a nonfunctional truncated protein. Together, these results demonstrate that yeast models can be used to characterize known and novel PMM2 patient alleles in quantitative growth and enzymatic activity assays, and used as patient avatars for PMM2-CDG drug screens yielding compounds that could be rapidly cross-validated in zebrafish, rodent and human organoid models.

KEYWORDS

Phosphomannomutase 2 Deficiency
PMM2-CDG
congenital disorders of glycosylation
yeast models of human disease
drug screens

Phosphomannomutase 2 deficiency (PMM2-CDG) is the most common congenital disorder of glycosylation (Ferreira *et al.* 2018), and was originally described in the literature as CDG1a/CDG1/Jaeken Syndrome (Matthijs *et al.* 1997). The glycosylation

pathway has been extensively studied and elucidated in yeast (Kukuruzinska *et al.* 1987; Tanner and Lehle 1987; Lehle *et al.* 2006). Owing to its conservation, many of the yeast genes in this pathway can be interchanged with their human orthologs. This enabled testing patient alleles directly in yeast and has been done for numerous genes associated with CDG including ALG1 (Takahashi *et al.* 2000; Schwarz *et al.* 2004), ALG12 (Grubenmann *et al.* 2002), ALG2 (Thiel *et al.* 2003), ALG3 (Körner *et al.* 1999), ALG8 (Schollen *et al.* 2004), ALG9 (Frank *et al.* 2004), and PGM3 (Mio *et al.* 2000). PMM2-CDG is an autosomal recessive, multi-organ monogenic disease displaying variable clinical progression and presentation. It is caused by an underlying enzymatic deficiency in PMM2 leading to cell-autonomous defects in the production of N-linked glycoproteins. Primarily affected organs include brain, liver, gastrointestinal tract,

Copyright © 2019 Lao *et al.*

doi: <https://doi.org/10.1534/g3.118.200934>

Manuscript received October 1, 2018; accepted for publication December 5, 2018; published Early Online December 7, 2018.

This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Supplemental material available at Figshare: <https://doi.org/10.25387/g3.7408367>.

¹Corresponding Author: 6000 Shoreline Ct Suite 204, South San Francisco, California 94080

heart, kidney, and most PMM2-CDG patients have intellectual disability and developmental delay (Schiff *et al.* 2017). PMM2-CDG is a global disease but the exact worldwide incidence of PMM2-CDG is unknown. There are currently no FDA-approved therapies for PMM2-CDG.

The yeast ortholog of PMM2, *SEC53*, was originally recovered as a *sec* (short for secretory) complementation group in forward genetics screens in the early 1980s. These studies culminated three decades later in the 2013 Nobel Prize in Medicine and Physiology (Ferro-Novick *et al.* 1984; Kepes & Schekman 1988). All PMM2 orthologs including *SEC53* isomerize mannose-6-phosphate (M6P) to mannose-1-phosphate (M1P), and are activated by glucose-1,6-bisphosphate (G16) and mannose-1,6-bisphosphate (M16) (Pirard *et al.* 1999). M1P is a precursor of GDP-mannose, which in turn is required for the production of dolichol phosphate mannose and then lipid-linked oligosaccharides (LLO) in the lumen of the endoplasmic reticulum. LLO are substrates for a cascade of enzymes that are individually linked to a CDG (Panneerselvam & Freeze 1996). The oligosaccharyltransferase (OST) complex executes the final steps of N-linked glycosylation by transferring the glycan from the LLO donor to asparagine residues of nascent proteins (Cherepanova *et al.* 2016). *sec53* yeast mutants grown at the non-permissive temperature accumulate hypoglycosylated forms of secretory proteins, leading to intracellular buildup of normally secreted proteins and ultimately cell death. Overexpression of human PMM2 in a *sec53* temperature-sensitive mutant rescued lethality (Hansen *et al.* 1997).

PMM2 activity has been studied *in vitro* using recombinant enzyme expressed in bacteria and in patient-cell-derived assays. PMM2 protein variants were expressed in *E. coli* and displayed enzymatic activities between 0% and 100% of control levels, with most missense alleles exhibiting activity between 16–54% of control levels (Kjaergaard *et al.* 1999; Vega *et al.* 2011). The limitation of this model system is that it fails to replicate heterodimer formation, which is almost always the case in PMM2-CDG patients. Patient fibroblasts, which are fast-dividing cells, have residual activity between 35–70% of control levels, and higher passage number is associated with increased basal PMM2 activity (Grünewald *et al.* 2001). Patient-derived leukocytes, which are terminally differentiated cells, have less background contaminating PMM2 enzymatic activity and show clear separation between cases and controls (Grünewald *et al.* 2001). Similarly, induced pluripotent stem cell (iPSC) clones have been derived from patient fibroblasts and they also display proteome-wide hypoglycosylation (Thiesler *et al.* 2016).

Attempts to create a viable PMM2 mouse model have been stymied at multiple turns. PMM2 knockout mice are early embryonic lethal (Thiel *et al.* 2006). Several years ago, a PMM2^{R141H/F119L} knock-in mouse model was generated, and it exhibits variable lethality starting prenatally with few postnatal escapers (Chan *et al.* 2016). Challenges in creating viable PMM2 mutant mice have encouraged parallel efforts to create disease models in other model organisms such as nematodes, flies and zebrafish. The nematode PMM2 ortholog (F52B11.2) is uncharacterized, and the first *Drosophila* model of PMM2 deficiency were published two years ago (Parkinson *et al.* 2016). Flies homozygous for strong loss-of-functions alleles for *pmm2* die during the larval stage. Flies in which the expression of *pmm2* is “knocked-down” using RNA interference in neurons have both morphological and physiological synaptic defects at the neuromuscular junction, and locomotor defects. A 2morpholino-induced PMM2 knockdown zebrafish model results in reduced N-linked glycosylation and LLO levels, along with

craniofacial and motor defects reminiscent of PMM2-CDG patients (Cline *et al.* 2012).

The relationship between PMM2-CDG clinical progression and presentation and PMM2 enzymatic activity measured using recombinant protein variants or in patient cell lysates has been opaque. On the one hand, the absence of R141H homozygotes indicates that similar to other monogenic inborn errors of metabolism, complete PMM2 deficiency is incompatible with human life. This is consistent with the lethality observed in PMM2 deficiency across model organisms (Matthijs *et al.* 1998; Schollen *et al.* 2000). R141H is a catalytic dead variant functionally equivalent to a knockout or genetic null. On the other hand, the over-abundance of missense mutations in PMM2 in large exome databases of control populations suggests that there could be heterozygote advantage to 50% PMM2 enzyme levels (Citro *et al.* 2018). That would also explain the high incidence of novel missense mutations *in trans* with R141H.

Hypoglycosylation and varying degrees of lethality are common phenotypes observed across all PMM2 animal models. These results suggest that the minimum threshold of PMM2 enzyme activity required for viability may vary depending on the physiological state of the cell, cell differentiation status and stage of organismal development. The differential susceptibility of cell types may be attributed to proteome-wide hypoglycosylation or loss of glycosylation of specific regulatory or housekeeping glycoproteins or a combination of both. The full extent of PMM2-CDG pathophysiology has not been elucidated, perhaps in part because model organism efforts have not been coordinated and focused on specific patient mutations. We turned to budding yeast to create foundational PMM2-CDG patient avatars for multiple uses, starting with growth-based phenotypic drug screens to rapidly identify therapeutic options tailored to specific patient mutation combinations.

METHODS

Strains and plasmids

All strains used in this study are in S288c background (Supplemental Table 1). Strains were grown in SC or SC drop out media (Sunrise Science) + 2% dextrose at 30° unless otherwise noted. Standard genetic procedures of transformation and tetrad analysis were followed to construct strains. *SEC53* rescue plasmid was generated by cloning the *SEC53* promoter, open reading frame, and terminator sequences into the episomal pRS316 containing the *URA3* selectable marker. *SEC53* variants were generated by cloning the relevant promoter, GFP or *SEC53* gene, and *CYC1* terminator sequences into an integrating plasmid containing the *LEU2* selectable marker and integrated at the *SwaI* restriction site into the *HO* locus. For PMM2 variants, the *SEC53* ORF was replaced with a codon-optimized PMM2. Plasmids were generated by Next Interactions (Richmond, CA, USA) or GenScript (Piscataway, NJ, USA). Strains were generated by Next Interactions or in-house.

Growth assay

Cells were picked from plates and resuspended in SC media to OD₆₀₀ = 1.0, then serially diluted into 50 μL SC+FOA media in 384-well plates at 10⁻¹, 10⁻², and 10⁻³. Plates were incubated at 30° and absorbance reading at 600 nm were measured by a plate reader (Molecular Devices SpectraMax M3) at the indicated time points. Plates were vortexed briefly to resuspend cells prior to plate readings. 5-fluoroortoc acid was purchased from US Biological and used at a concentration of 1 mg/L.




Figure 2 Comparison of growth of yeast SEC53 haploid alleles. A. Graphs show growth of 10^{-2} dilution of OD 1.0 cells over time at 30° in 50 μ L SC+FOA media in a 384-well plate. 1X indicates the native SEC53 promoter. 2X indicates double the native promoter strength (pACT1). 10X indicates 10X the native promoter strength (pTEF1). 0.2X indicates 20% of the native promoter strength (pREV1). B. Comparison of growth relative to wildtype SEC53 at a single time point ($t = 20$). Cell density of each strain at $t = 20$ was normalized against its corresponding promoter match SEC53 wildtype at $t = 20$. However, because pREV1-WT grows slower than wildtype cells, all pREV1 strains were normalized against pSEC53-WT at $t = 20$.

30° for 16 – 21 hr until OD₆₀₀ reaches ~ 0.8 . Plates were vortexed briefly to resuspend cells prior to reading.

Validation

Microsource Spectrum compounds were reordered from MicroSource Discovery Systems and resuspended in DMSO. 5 – 125 nL compounds or DMSO were dispensed into 384-well plates and 50 μ L of yeast cell suspensions or media were dispensed by multichannel pipettes to achieve the desired concentration. Plates were covered and incubated at 30° for 16 – 23 hr until OD₆₀₀ reaches ~ 0.8 . Plates were vortexed briefly to resuspend cells prior to plate readings.

Data availability

Supplemental material available at Figshare: <https://doi.org/10.25387/g3.7408367> and consists of a list of strains and plasmids (Table S1) and five figures.

RESULTS

Modeling PMM2 patient alleles in yeast SEC53

PMM2 and SEC53 are orthologs that share 55% identity at the amino-acid level (Figure 1A). We generated three common PMM2 disease-causing alleles R141H, F119L, and V231M, and two less well studied pathogenic alleles: E93A and E139K (Figure 1B). The positions of these residues are indicated in Figure 1C. R141 is in the substrate-binding domain of PMM2 (Andreotti *et al.* 2015). R141H has no detectable enzymatic activity and never occurs in homozygosity in patients despite being the most commonly observed mutation (Kjaergaard *et al.* 1999). F119 is a component of the hydrophobic core within the dimer interface and is the second most commonly observed mutation (Silvaggi *et al.* 2006). F119L has 25% enzymatic activity *in vitro* and this deficiency is likely due to its diminished ability to dimerize and decreased dimer stability (Kjaergaard *et al.* 1999; Pirard *et al.* 1999; Andreotti *et al.* 2015). V231 is in the interior of the core domain and a mutation in this residue is detrimental to its native protein

structure (Silvaggi *et al.* 2006; Citro *et al.* 2018). The folding and stability defect of the V231M allele contributes to its reported reduced *in vitro* enzymatic activity of 38.5% (Kjaergaard *et al.* 1999; Pirard *et al.* 1999). Existing data on E93A and E139K variants are limited. E93 directly interacts with R116 *in trans* within the PMM2 dimer and a mutation in this residue likely compromises dimerization (Andreotti *et al.* 2015). E139K is a result of a 415G > A transition mutation in the genomic sequence that interferes with RNA splicing, causing either skipping of exon 5 to form a partially deleted and nonfunctional protein or a full-length E139K mutant protein (Vuillaumier-Barrot *et al.* 1999).

PMM2 F119L, R139K, R141H, and V231M correspond to SEC53 F126L, E146K, R148H, and V238M, respectively. SEC53 E100K was unintentionally generated, but the residue is conserved in PMM2 and the patient allele is E93A. Some of these variants have low to no detectable enzymatic activity reported in the literature, so we placed the mutants under different promoters to determine if changes in protein abundance affect viability of each variant. The relative strength of the TEF1, ACT1, and REV1 promoters were compared to the native SEC53 promoter by driving expression of the green fluorescent protein (GFP) (Figure 1D). Based on fluorescence reading by flow cytometry, we found that relative to the native SEC53 promoter, the strength of TEF1, ACT1, and REV1 promoters are 10X, 2X, and 0.2X, respectively.

Growth of Sec53 variants correlates with enzymatic defects of the variant and promoter strength

To overcome the complication that SEC53 is an essential gene, we placed a wildtype SEC53 copy on a URA3 plasmid that we can conditionally remove by growing cells in 5-fluoroorotic acid (5-FOA). 5-FOA is an analog of uracil that is converted into a toxic intermediate in cells where the uracil biosynthetic pathway is active, which the URA3 marker enables. Each SEC53 variant is then individually integrated at the HO locus of sec53Δ cells. The phenotype of each variant is revealed when the wildtype URA3 containing plasmid is counter-selected in media containing 5-FOA.




Figure 3 Comparison of growth of yeast SEC53 diploid alleles. Graphs show growth of 10^{-2} dilution of OD 1.0 cells over time at 30°C in 50 μ L SC+FOA media in a 384-well plate. 1X indicates the native SEC53 promoter. 2X indicates double the native promoter strength (pACT1). 10X indicates 10X the native promoter strength (pTEF1). 0.2X indicates 20% of the native promoter strength (pREV1). Bar graphs show comparison of growth relative to homozygous wildtype SEC53 diploids at a single time point (t = 20 hr). Strains with the indicated promoter are listed in the legend: A) SEC53-F126L, B) SEC53-V238M, C) SEC53-E100K, and D) SEC53-E146K.

Increasing the expression level of the hypomorphic alleles improves their growth in every case except the R148H variant and the *sec53Δ* negative control (Figure 2A, B, and Supplemental Figure 1). When expressed at native level, the V238M allele is sufficient for growth, but

at a slower rate and achieving a lower final yield than wildtype cells (32%). Doubling the expression of the V238M allele with the ACT1 promoter restores growth of this mutant: 67% at 20 hr and near wildtype final yield at 24 hr. The F126L allele grows poorly under the




Figure 4 Expression of human PMM2 rescues growth of yeast *sec53Δ* cells. A. Expression of the indicated human PMM2 variant under the SEC53 promoter. B. Expression of the indicated human PMM2 variant under the ACT1 or TEF1 promoter. Left panels show growth over time and right panels show growth relative to wildtype SEC53 at t = 20 hr.

endogenous promoter (27%), and also grows better when its expression is doubled (57%). The relative growth of F126L and V238M is consistent with their reported residual *in vitro* enzymatic activity (Pirard *et al.*, 1999). Over-expression of F126L and V238M alleles under the TEF1 promoter completely rescues these cells. E100K is viable only under the ACT1 (16%) and TEF1 (67%) promoters, which indicates the severity of this mutation compared to the other variants. On the other hand, the R148H null allele is not compatible with growth at any promoter strength and phenocopies the genetic null *sec53Δ*. Together, these data can be fully explained by mass action effects, where a reduction in enzymatic activity can be overcome by increasing the total amount of enzyme in the cell.

In contrast, reducing wildtype SEC53 mRNA expression to 20% of its native level with the REV1 promoter modestly, but consistently, compromises cell growth to 64% of the control (Figure 2A and B). This result shows that yeast cells are highly sensitive to the total amount of SEC53 protein. Interestingly, there was no toxicity associated with 10-fold over-expression of wildtype SEC53. Similar to wildtype, the E146K variant is defective only at the lowly expressing REV1 promoter (69%). This result suggests that the splicing defect of the 415G > A mutation in humans may reduce the abundance of still functional PMM2 E139K proteins to a sub-critical amount below the threshold for viability.

Comparing the strains relative to one another at a single time-point, we can see that the severity of growth defects of the SEC53 alleles correlates with the level of residual enzymatic activity of the PMM2 alleles reported using bacterial recombinant protein and PMM2-CDG patient fibroblasts (Figure 2B).

SEC53 diploid variants recapitulate the growth of haploid variants

Most PMM2-CDG patients are compound heterozygotes with a recurring or novel mutation (usually missense) paired with the R141H null

allele. The most common genotype is PMM2^{F119L/R141H}. To further study genotype-phenotype relationships of the SEC53 variants, we generated homozygous and compound heterozygous diploids (Figure 3 and Supplemental Figure 2). As expected, a single copy of wildtype SEC53 is sufficient for normal diploid cell growth and there is no growth difference between homozygous wildtype and heterozygous SEC53^{+/R148H} cells (Figure 3A).

Homozygous F126L diploids grow slower than their respective F126L/R148H heterozygous diploids (Figure 3A). In both 1X and 2X expression regimes, R148H heterozygosity improves growth. Normalizing to wildtype at 20 hr, the growth of pACT-F126L/F126L is 52% compared to 66% in pACT1-F126L/R148H. pSEC53-F126L/F126L is 21% compared to 41% in pSEC53-F126L/R148H. These results could be explained by the diminished ability of the PMM2 F126L variant to homodimerize, and the presence of R148H monomers allows formation of hemi-functional F126L:R148H heterodimers (Andreotti *et al.* 2015). On the other hand, V238M causes protein misfolding but properly folded V238M monomers are competent to dimerize. The pSEC53-V238M/V238M homozygous diploid (43%) grows similarly to the pSEC53-V238M/R148H heterozygous diploid (46%) (Figure 3B). However, at the final 24 hr timepoint the pSEC53-V238M/V238M homozygous diploid (OD₆₀₀ = 0.93 ± 0.01) was growing better than the pSEC53-V238M/R148H heterozygous diploid (OD₆₀₀ = 0.79 ± 0.2). This could be explained by the excess of R148H monomers relative to V238M monomers resulting in formation of nonfunctional R148H:R148H homodimers at a higher rate than hemi-functional V238M:R148H heterodimers.

Just as in the case of the dimerization-defective F126L variant, E100K homozygous diploids grew more poorly than E100K/R148H heterozygous diploids, which in turn grew more slowly than E100K/WT diploids (Figure 3C). Under the TEF1 promoter, E100K/E100K is 53% compared to 99% in E100K/WT and 100% in E100K/R148H.




Figure 5 Phosphomannomutase activity of SEC53 alleles. A. Graphs showing NADPH formation over time in 200 μ L reaction with 0.1 μ g/mL protein lysate from the strains indicated. B. Phosphomannomutase activity (at 40 min) of the indicated SEC53 variant relative to pSEC53-WT plotted against its cell growth (at 20 hr) relative to pSEC53-WT.

Under the *ACT1* promoter, E100K/E100K is 8% compared to 100% in E100K/WT and 78% in E100K/R148H. Like F126, E100 is expected to affect dimerization and R148H may facilitate the formation of partially functional heterodimers. E146K, which is indistinguishable from wildtype, grew as expected except with the *REV1* promoter: pREV1-E146K/E146K homozygous diploids (96%) grow better compared to the E146K/R148H heterozygous diploids (66%) (Figure 3D). One explanation is that the presence of R148H monomers results in fewer E146K:E146K homodimers which is still compatible with viability but not maximal growth rate.

The phenotypes of human PMM2 alleles in yeast parallel SEC53 alleles

It was previously demonstrated that expression of human PMM2 rescues the lethality of a temperature-sensitive allele of *SEC53*, *sec53-6* (Hansen *et al.* 1997). We initially expressed human PMM2 cDNA but this failed to rescue yeast *sec53* Δ . For the first time we show that expression of human PMM2 cDNA that is codon-optimized for expression in yeast does in fact rescue *sec53* Δ (Figure 4 and Supplemental Figure 3). This suggests that the non-codon-optimized PMM2 was likely poorly expressed in yeast such that it was not sufficient for growth under the native *SEC53* promoter. Subsequently, we expressed each of the human PMM2 variants in *sec53* Δ cells to determine whether PMM2 alleles behave the same as *SEC53* alleles. Under the *SEC53* promoter, PMM2 partially rescues *sec53* Δ to 71% of wildtype yeast *SEC53* (Figure 4A). The degree to which each PMM2 variant rescues *sec53* Δ correlates with their reported residual enzymatic activity and supports the conclusion that the biochemical defect of each allele is conserved between yeast and humans. PMM2 E139K (68%) grows similarly to wildtype PMM2, in agreement with yeast *SEC53* E146K. V231M compromises growth (56%) and F119L

further compromises growth (45%). E93A, on the other hand, is not sufficient for growth under the *SEC53* promoter and does not restore growth above *sec53* Δ cells. This is consistent with pSEC53-E100K and further supports the essentiality of E93 in PMM2 function.

Expressing PMM2 under the *ACT1* promoter improves growth to 97% (Figure 4B). Expectedly, doubling the expression of F119L with the *ACT1* promoter also improves its growth to 64%. Under the *TEF1* promoter, PMM2 completely rescues *sec53* Δ cells. This suggests that PMM2 expressed in yeast may not be functioning optimally and requires higher expression levels. As is the case with *SEC53*, 10-fold over-expression of PMM2 is not cytotoxic. Based on these results, we can characterize the deficiency of a given PMM2 allele in yeast based on its effect on cell growth over a range of protein expression regimes and in different compound heterozygous combinations.

Measuring phosphomannomutase activity levels in SEC53 variants

We performed a PMM2 enzymatic assay to determine whether the expression level of the variants correlates with the enzymatic activity measured in wildtype and mutant yeast cell lysates. We assayed phosphomannomutase (PMM) activity by measuring the reduction of NADP⁺ to NADPH spectrophotometrically at 340 nm with a plate reader (Van Schaftingen & Jaeken 1995; Pirard *et al.* 1999; Kjaergaard *et al.* 1999; Sharma *et al.* 2011; and Citro *et al.* 2017). NADPH production is achieved by a series of four enzyme-coupled reactions shown in Supplemental Figure 4A. Mannose-1-phosphate and NADP⁺ are provided as substrates for the reactions along with phosphomannose isomerase, phosphoglucose isomerase, glucose-6-phosphoate dehydrogenase, and PMM2 from the protein lysate. Additionally, glucose 1,6-bisphosphate is used as an activator of PMM2 activity.




Figure 6 Summary of the 2,560 drug repurposing screen. A. Comparison of z-scores between the negative (blue) vs. positive (red) controls of representative datasets show separation of data. B. Comparison of z-scores between replicates show positive correlation between duplicate datasets. C. Pre-hit compounds and z-scores. We identified six compounds from the Microsource Spectrum library that showed a z-score of ≥ 2.0 in growth in at least 2 replicates of the same allele (orange). Green indicates a z-score of ≥ 2.0 , but did not replicate in the duplicate screen.

We determined that wildtype *SEC53* expression level and growth correlates to the PMM activity detected by the assay (Figure 5A, B, and Supplemental Figure 4B). Lysates from pTEF1 and pACT1 cells consistently show elevated activity compared to pSEC53 cells. Lysates from pREV1-*SEC53* cells show less activity (53%), consistent with its growth relative (66%) to pSEC53-*SEC53*. For V238M, the expression level correlates with enzymatic assay and with growth, but not to the extent expected (Figure 5B). For example, pTEF1-V238M rescues growth completely (100%), but PMM activity in these cells are well below wildtype cells (11%) (Figure 5B). pACT1-V238M also rescue growth to a higher degree than the enzymatic activity (16%) of these cells would indicate. This is also true for F126L (Figure 5B). However, pACT1-F126L (7%) and pSEC53-F126L (7%) does not show significant difference in PMM activity. This indicates that for *SEC53* mutations, either mannose-1-phosphate levels or PMM enzymatic activity in cell lysates does not necessarily reflect the growth of these cells. In other words, *SEC53* variants may only require a modest boost in PMM enzymatic activity

and/or mannose-1-phosphate levels above their baselines to achieve maximal growth rate and presumably a fully glycosylated proteome.

Drug repurposing screen in yeast models of PMM2-CDG identified three novel chemical modifiers

We advanced pACT1-F126L, pSEC53-V238M, and pSEC53-F126L haploids and pACT1-F126L/pACT1-R148H, pSEC53-V238M/pSEC53-R148H, and pSEC53-F126L/pSEC53-R148H heterozygous diploids to high-throughput drug screens. Screening was done with a 2,560 compound MicroSource Spectrum library consisting of FDA approved drugs, bioactive tool compounds, and natural products. Each strain was screened in duplicate in 384-well plates, with each plate containing 32 wells of the negative control (no drugs) and 24 wells of the positive controls (wildtype cells). As shown in Figure 6A, the positive and negative controls showed good separation of Z-scores, which allowed us to distinguish even a relatively modest rescue of growth in the screen. Additionally, there is good correlation between




Figure 7 Three compounds show differential rescue of growth of SEC53 variants. A. Growth of cells in alpha-cyano-4-hydroxycinnamic acid at the indicated dose relative to growth in the absence of compound (0 μ M). B. Growth of cells in 2',2'-biseipigallocatechin digallate at the indicated dose relative to growth in the absence of compound (0 μ M). C. Growth of cells in suramin hexasodium at the indicated dose relative to growth in the absence of compound (0 μ M). D. Growth of cells in cysteamine hydrochloride (negative control) at the indicated dose relative to growth in the absence of compound (0 μ M).

replicates (correlation >0.4 for all panels) (Figure 6B). With a Z-score cutoff of 2.0, we identified six “pre-hit” compounds that looked promising because their ability to rescue growth is conserved between the haploid and diploid strains (Figure 6C).

We reordered these compounds from the vendor as dry powder to retest them in multi-point dose response assays. We found that three of the six compounds showed consistent and dose-dependent rescues in haploid and heterozygous diploid cells, as defined by an improvement of greater than 10% in growth (Figure 7A-C, and Supplemental Figure 7). The negative control compound cysteamine hydrochloride

did not rescue at any dose (Figure 7D). At the maximum dose tested of 100 μ M, alpha-cyano-4-hydroxycinnamic acid rescues the F126L allele by 18% in haploid and 25% in diploid cells. Interestingly, this rescue is specific to the 2X PACT1 expression level (Figure 7A).

2'-2'-biseipigallocatechin digallate rescues growth of pSEC53-F126L and pSEC53-V238M cells and exerts a stronger response in heterozygous diploid cells than haploids (Figure 7B). Growth of pSEC53-F126L improved by as much as 11% at 25 μ M and pSEC53-F126L/R148H by 25% at 100 μ M. pSEC53-V238M improved by 19% at 50 μ M and pSEC53-V238M/R148H by 58% at 100 μ M. In the pACT1-F126L context, it

only rescues the heterozygous diploid pACT1-F126L/R148H cells (14% at 50 μ M) (Figure 7B).

Similarly, suramin hexasodium also rescues growth of the pSEC53 variants more than the pACT1 variants, and diploids more strongly than haploids (Figure 7C). At 100 μ M, growth of pSEC53-F126L improved by 25%, pSEC53-F126L/R148H by 47%, pSEC53-V238M by 16%, and pSEC53-V238M/R148H by 39%. In contrast, pACT1-F126L/R148H cells showed 23% improvement.

In summary, we found that alpha-cyano-4-hydroxycinnamic acid specifically rescues pACT1-F126L cells, while 2'-2'-bisepigallocatechin digallate and suramin hexasodium preferentially rescue pSEC53-F126L/R148H and pSEC53-V238M/R148H heterozygous diploid cells.

DISCUSSION

We created new yeast models of the congenital disorder of glycosylation PMM2-CDG and demonstrated their relevance toward developing therapeutics in four ways. First, yeast-codon-optimized human PMM2 fully rescues the lethality of *sec53* Δ cells. Second, each of the five pathogenic PMM2 missense mutations studied herein and their orthologous SEC53 mutations support comparable yeast cell growth in a *sec53* Δ whole-gene deletion background. The rank-ordered severity of the mutation pairs from weakest to strongest loss-of-function is: E139K & E146K >> V231M & V238M > F119L & F126L >> E93A & E100K >> R141H & R148H. Third, the residual enzymatic activities reported in the literature for the five PMM2 variants are correlated to the extent of yeast cell growth rescued by these variants. Fourth, a pilot drug repurposing screen successfully identified three compounds – an FDA approved drug, a tool compound and a GRAS (generally recognized as safe) plant-based natural product.

The three most well studied variants – R141H, F119L and V231M – all behaved as expected in haploid and homozygous diploid cells. A residual PMM2 enzymatic activity is not reported for bacterially expressed recombinant E93A protein, and our results clearly indicate the strong loss-of-function of both E93A and E100K variants in haploid and homozygous diploid cells. Contrary to the reported 25% residual PMM2 enzymatic activity of the E139K variant, our results indicate that both E139K and E146K variants grow similarly to wildtype controls with only a modest growth defect evident at the lowest expressing REV1 promoter, or 20% of the native SEC53 promoter strength. The two dimerization-defective variants F126L and E100K grew better when *in trans* with R148H than as homozygotes because R148H monomers can dimerize with either F126L or E100K monomers to form hemi-functional heterodimers. On the other hand, the known strongly folding-defective variant V238M and the weakly hypomorphic variant E146K grew better in homozygosity than *in trans* with R148H. We speculate that a larger pool of R148H monomers relative to V238M or E146K monomers due to the greater stability of the former results in a higher proportion of nonfunctional R148H:R148H homodimers diluting the total pool of fully functional V238M or E146K homodimers. Collectively, these results suggest two different therapeutic approaches, one for when a PMM2 allele is dimerization defective and another for when a PMM2 allele is folding defective or prone to aggregation and rapid turnover.

Based on the results of the phosphomannomutase enzymatic assay we adapted for yeast cell lysates, we challenge the reported residual enzymatic activities of F119L and V231M as 25% and 37.5% of control levels, which were determined using bacterially expressed recombinant PMM2 variants. Our data showed lower residual phosphomannomutase activity with V238M at ~10% of control levels and that of F119L at ~7% of control levels. In our hands, PMM2^{F119L/R141H} patient

fibroblast cells show 10% enzymatic activity. We infer from the severe growth defects of SEC53 E100K strains that the residual enzymatic activity of the E93A variant must be less than that of F119L and below 7%.

The pharmacology of the three hits from the Microsource Spectrum screen suggests possible explanations for rescue of PMM2-CDG involving antioxidant effects and perturbation of glycolysis. alpha-cyano-4-hydroxycinnamic acid has been described as a monocarboxylate transporter inhibitor (Diers *et al.* 2012) as well as an aldose reductase inhibitor (Zhang *et al.* 2016). 2'-2'-bisepigallocatechin digallate is also known as theasinensin, an active compound in oolong tea, and has numerous antioxidant properties shared by other plant-based polyphenols (Butt *et al.* 2014). Suramin is an FDA approved drug for African sleeping sickness and river blindness, and its mechanism of action against trypanosomes involves perturbations to N-acetylglucosamine biosynthesis (Alsford *et al.* 2012). Future experiments include testing whether any of these three compounds rescue PMM2 enzymatic activity in patient fibroblasts.

These yeast based PMM2-CDG patient avatars not only can be used to identify potential therapeutics demonstrated in this study, but can also be used in genetic modifier screens, genetic interaction screens, and basic studies to elucidate the pathophysiological cascade of PMM2-CDG starting at the cellular level and working up in model organism complexity.

ACKNOWLEDGMENTS

We thank Maggie's PMM2-CDG Cure, LLC and the Carmichael family for funding this work. We thank Next Interactions for the initial construct engineering and growth experiments, and Dr. Sangeetha Iyer for comments and feedback on the manuscript.

LITERATURE CITED

- Alsford, S., S. Eckert, N. Baker, L. Glover, A. Sanchez-Flores *et al.*, 2012 High-throughput decoding of antitrypanosomal drug efficacy and resistance. *Nature* 482: 232–236. <https://doi.org/10.1038/nature10771>
- Andreotti, G., M. C. Monti, V. Citro, and M. V. Cubellis, 2015 Heterodimerization of Two Pathological Mutants Enhances the Activity of Human Phosphomannomutase2. *PLoS One* 10: e0139882. <https://doi.org/10.1371/journal.pone.0139882>
- Butt, M. S., A. Imran, M. K. Sharif, R. S. Ahmad, H. Xiao *et al.*, 2014 Black tea polyphenols: a mechanistic treatise. *Crit. Rev. Food Sci. Nutr.* 54: 1002–1011. <https://doi.org/10.1080/10408398.2011.623198>
- Chan, B., M. Clasquin, G. A. Smolen, G. Histen, J. Powe *et al.*, 2016 A mouse model of a human congenital disorder of glycosylation caused by loss of PMM2. *Hum. Mol. Genet.* 25: 2182–2193. <https://doi.org/10.1093/hmg/ddw085>
- Cherepanova, N., S. Shrimal, and R. Gilmore, 2016 N-linked glycosylation and homeostasis of the endoplasmic reticulum. *Curr. Opin. Cell Biol.* 41: 57–65. <https://doi.org/10.1016/j.ceb.2016.03.021>
- Citro, V., C. Cimmaruta, M. Monticelli, G. Riccio, B. Hay Mele *et al.*, 2018 The Analysis of Variants in the General Population Reveals That PMM2 Is Extremely Tolerant to Missense Mutations and That Diagnosis of PMM2-CDG Can Benefit from the Identification of Modifiers. *Int. J. Mol. Sci.* 19: 2218–2230. <https://doi.org/10.3390/ijms19082218>
- Cline, A., N. Gao, H. Flanagan-Steet, V. Sharma, S. Rosa *et al.*, 2012 A zebrafish model of PMM2-CDG reveals altered neurogenesis and a substrate-accumulation mechanism for N-linked glycosylation deficiency. *Mol. Biol. Cell* 23: 4175–4187. <https://doi.org/10.1091/mbc.e12-05-0411>
- Diers, A. R., K. A. Broniowska, C. F. Chang, and N. Hogg, 2012 Pyruvate fuels mitochondrial respiration and proliferation of breast cancer cells: effect of monocarboxylate transporter inhibition. *Biochem. J.* 444: 561–571. <https://doi.org/10.1042/BJ20120294>
- Ferreira, C. R., R. Altassan, D. Marques-Da-Silva, R. Francisco, J. Jaeken *et al.*, 2018 Recognizable phenotypes in CDG. *J. Inherit. Metab. Dis.* 41: 541–553. <https://doi.org/10.1007/s10545-018-0156-5>

- Ferro-Novick, S., W. Hansen, I. Schauer, and R. Schekman, 1984 Genes required for completion of import of proteins into the endoplasmic reticulum in yeast. *J. Cell Biol.* 98: 44–53. <https://doi.org/10.1083/jcb.98.1.44>
- Frank, C. G., C. E. Grubenmann, W. Eyaid, E. G. Berger, M. Aebi *et al.*, 2004 Identification and functional analysis of a defect in the human ALG9 gene: definition of congenital disorder of glycosylation type II. *Am. J. Hum. Genet.* 75: 146–150. <https://doi.org/10.1086/422367>
- Grubenmann, C. E., C. G. Frank, S. Kjaergaard, E. G. Berger, M. Aebi *et al.*, 2002 ALG12 mannosyltransferase defect in congenital disorder of glycosylation type Ig. *Hum. Mol. Genet.* 11: 2331–2339. <https://doi.org/10.1093/hmg/11.19.2331>
- Grünewald, S., E. Schollen, E. Van Schaftingen, J. Jaeken, and G. Matthijs, 2001 High residual activity of PMM2 in patients' fibroblasts: possible pitfall in the diagnosis of CDG-Ia (phosphomannomutase deficiency). *Am. J. Hum. Genet.* 68: 347–354. <https://doi.org/10.1086/318199>
- Hansen, S. H., S. R. Frank, and J. E. Casanova, 1997 Cloning and characterization of human phosphomannomutase, a mammalian homologue of yeast SEC53. *Glycobiology* 7: 829–834. <https://doi.org/10.1093/glycob/7.6.829>
- Kepes, F., and R. Schekman, 1988 The yeast SEC53 gene encodes phosphomannomutase. *J. Biol. Chem.* 263: 9155–9161.
- Kjaergaard, S., F. Skovby, and M. Schwartz, 1999 Carbohydrate-deficient glycoprotein syndrome type 1A: expression and characterisation of wild type and mutant PMM2 in *E. coli*. *Eur. J. Hum. Genet.* 7: 884–888. <https://doi.org/10.1038/sj.ejhg.5200398>
- Körner, C., R. Knauer, U. Stephani, T. Marquardt, L. Lehle *et al.*, 1999 Carbohydrate deficient glycoprotein syndrome type IV: deficiency of dolichyl-P-Man:Man(5)GlcNAc(2)-PP-dolichyl mannosyltransferase. *EMBO J.* 18: 6816–6822. <https://doi.org/10.1093/emboj/18.23.6816>
- Kukuruzinska, M. A., M. L. E. Bergh, and B. J. Jackson, 1987 Protein Glycosylation in Yeast. *Annu. Rev. Biochem.* 56: 915–944. <https://doi.org/10.1146/annurev.bi.56.070187.004411>
- Lehle, L., S. Strahl, and W. Tanner, 2006 Protein glycosylation, conserved from yeast to man: a model organism helps elucidate congenital human diseases. *Angew. Chem. Int. Ed. Engl.* 45: 6802–6818. <https://doi.org/10.1002/anie.200601645>
- Matthijs, G., E. Schollen, E. Pardon, M. Veiga-Da-Cunha, J. Jaeken *et al.*, 1997 Mutations in PMM2, a phosphomannomutase gene on chromosome 16p13, in carbohydrate-deficient glycoprotein type I syndrome (Jaeken syndrome). *Nat. Genet.* 16: 88–92. Erratum 16: 316. <https://doi.org/10.1038/ng0597-88>
- Matthijs, G., E. Schollen, E. Van Schaftingen, J. J. Cassiman, and J. Jaeken, 1998 Lack of homozygotes for the most frequent disease allele in carbohydrate-deficient glycoprotein syndrome type 1A. *Am. J. Hum. Genet.* 62: 542–550. <https://doi.org/10.1086/301763>
- Mio, T., T. Yamada-Okabe, M. Arisawa, and H. Yamada-Okabe, 2000 Functional cloning and mutational analysis of the human cDNA for phosphoacetylglucosamine mutase: identification of the amino acid residues essential for the catalysis. *Biochim. Biophys. Acta* 1492: 369–376. [https://doi.org/10.1016/S0167-4781\(00\)00120-2](https://doi.org/10.1016/S0167-4781(00)00120-2)
- Panneerselvam, K., and H. H. Freeze, 1996 Mannose corrects altered N-glycosylation in carbohydrate-deficient glycoprotein syndrome fibroblasts. *J. Clin. Invest.* 97: 1478–1487. <https://doi.org/10.1172/JCI118570>
- Parkinson, W. M., M. Dookwah, M. L. Dear, C. L. Gatto, K. Aoki *et al.*, 2016 Synaptic roles for phosphomannomutase type 2 in a new *Drosophila* congenital disorder of glycosylation disease model. *Dis. Model. Mech.* 9: 513–527. <https://doi.org/10.1242/dmm.022939>
- Pirard, M., Y. Achouri, J. F. Collet, E. Schollen, G. Matthijs *et al.*, 1999 Kinetic properties and tissular distribution of mammalian phosphomannomutase isozymes. *Biochem. J.* 339: 201–207. <https://doi.org/10.1042/bj3390201>
- Schiff, M., C. Roda, M. L. Monin, A. Arion, M. Barth *et al.*, 2017 Clinical, laboratory and molecular findings and long-term follow-up data in 96 French patients with PMM2-CDG (phosphomannomutase 2-congenital disorder of glycosylation) and review of the literature. *J. Med. Genet.* 54: 843–851. <https://doi.org/10.1136/jmedgenet-2017-104903>
- Schollen, E., C. G. Frank, L. Keldermans, R. Reyntjens, C. E. Grubenmann *et al.*, 2004 Clinical and molecular features of three patients with congenital disorders of glycosylation type Ih (CDG-Ih) (ALG8 deficiency). *J. Med. Genet.* 41: 550–556. <https://doi.org/10.1136/jmg.2003.016923>
- Schollen, E., S. Kjaergaard, E. Legius, M. Schwartz, and G. Matthijs, 2000 Lack of Hardy-Weinberg equilibrium for the most prevalent PMM2 mutation in CDG-Ia (congenital disorders of glycosylation type Ia). *Eur. J. Hum. Genet.* 8: 367–371. <https://doi.org/10.1038/sj.ejhg.5200470>
- Schwarz, M., C. Thiel, J. Lübbehusen, B. Dorland, T. de Koning *et al.*, 2004 Deficiency of GDP-Man:GlcNAc2-PP-dolichol mannosyltransferase causes congenital disorder of glycosylation type Ik. *Am. J. Hum. Genet.* 74: 472–481. <https://doi.org/10.1086/382492>
- Sharma, V., M. Ichikawa, P. He, D. A. Scott, Y. Bravo *et al.*, 2011 Phosphomannose isomerase inhibitors improve N-glycosylation in selected phosphomannomutase-deficient fibroblasts. *J. Biol. Chem.* 286: 39431–39438. <https://doi.org/10.1074/jbc.M111.285502>
- Silvaggi, N. R., C. Zhang, Z. Lu, J. Dai, D. Dunaway-Mariano *et al.*, 2006 The X-ray crystal structures of human alpha-phosphomannomutase 1 reveal the structural basis of congenital disorder of glycosylation type Ia. *J. Biol. Chem.* 281: 14918–14926. <https://doi.org/10.1074/jbc.M601505200>
- Takahashi, T., R. Honda, and Y. Nishikawa, 2000 Cloning of the human cDNA which can complement the defect of the yeast mannosyltransferase I-deficient mutant alg 1. *Glycobiology* 10: 321–327. <https://doi.org/10.1093/glycob/10.3.321>
- Tanner, W., and L. Lehle, 1987 Protein glycosylation in yeast. *Biochim. Biophys. Acta* 906: 81–99. [https://doi.org/10.1016/0304-4157\(87\)90006-2](https://doi.org/10.1016/0304-4157(87)90006-2)
- Thiel, C., T. Lübke, G. Matthijs, K. von Figura, and C. Körner, 2006 Targeted disruption of the mouse phosphomannomutase 2 gene causes early embryonic lethality. *Mol. Cell. Biol.* 26: 5615–5620. <https://doi.org/10.1128/MCB.02391-05>
- Thiel, C., M. Schwarz, J. Peng, M. Grzmil, M. Hasilik *et al.*, 2003 A new type of congenital disorders of glycosylation (CDG-Ii) provides new insights into the early steps of dolichol-linked oligosaccharide biosynthesis. *J. Biol. Chem.* 278: 22498–22505. <https://doi.org/10.1074/jbc.M302850200>
- Thiesler, C. T., S. Cajic, D. Hoffmann, C. Thiel, L. van Diepen *et al.*, 2016 Glycomic Characterization of Induced Pluripotent Stem Cells Derived from a Patient Suffering from Phosphomannomutase 2 Congenital Disorder of Glycosylation (PMM2-CDG). *Mol. Cell. Proteomics* 15: 1435–1452. <https://doi.org/10.1074/mcp.M115.054122>
- Van Schaftingen, E., and J. Jaeken, 1995 Phosphomannomutase deficiency is a cause of carbohydrate-deficient glycoprotein syndrome type I. *FEBS Lett.* 377: 318–320. [https://doi.org/10.1016/0014-5793\(95\)01357-1](https://doi.org/10.1016/0014-5793(95)01357-1)
- Vega, A. I., C. Pérez-Cerdá, D. Abia, A. Gámez, P. Briones *et al.*, 2011 Expression analysis revealing destabilizing mutations in phosphomannomutase 2 deficiency (PMM2-CDG). *J. Inher. Metab. Dis.* 34: 929–939. <https://doi.org/10.1007/s10545-011-9328-2>
- Vuillaumier-Barrot, S., A. Barnier, M. Cuer, G. Durand, B. Grandchamp *et al.*, 1999 Characterization of the 415G>A (E139K) PMM2 mutation in carbohydrate-deficient glycoprotein syndrome type Ia disrupting a splicing enhancer resulting in exon 5 skipping. *Hum. Mutat.* 14: 543–544. [https://doi.org/10.1002/\(SICI\)1098-1004\(199912\)14:6<543::AID-HUMU17>3.0.CO;2-S](https://doi.org/10.1002/(SICI)1098-1004(199912)14:6<543::AID-HUMU17>3.0.CO;2-S)
- Zhang, L., Y. F. Li, S. Yuan, S. Zhang, H. Zheng *et al.*, 2016 Bioactivity Focus of α -Cyano-4-hydroxycinnamic acid (CHCA) Leads to Effective Multifunctional Aldose Reductase Inhibitors. *Sci. Rep.* 6: 24942. <https://doi.org/10.1038/srep24942>

Communicating editor: M. Smolka